id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-287758-da11ypiy	Mônica Vitalino de Almeida, Sinara	COVID-19 therapy: what weapons do we bring into battle?	2020-09-10		.txt	text/plain	17412	1034	45	The increase in studies related to SARS-CoV-2 during the first semester in 2020 has allowed the rather speedy identification of promising therapeutic targets for both developing immunotherapies and producing/identifying antiviral drugs. 5, 64 So far, structural proteins and enzymes that participate actively in the process of viral replication are the most investigated targets for the development of molecules for anti-CoVs therapies (FIG. Based on results from previous studies as well, nelfinavir was considered a likely therapy for COVID-19 after its indication for clinical trials as a promising anti-SARS drug. 218 In addition to this well-known antitumor effect, imatinib has also shown in-vitro antiviral properties against several virus, such as infectious bronchitis virus (a viral model for studying the role of tyrosine kinase activity during CoV infection), by interfering with virus-cell fusion, 219 and other RNA viruses including coxsackie virus, 220 hepatitis C virus, 221 Ebola, 222 among others, mainly by blocking viral entry or egress from the host cell.	./cache/cord-287758-da11ypiy.txt	./txt/cord-287758-da11ypiy.txt